Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.28USD
18 May 2018
Change (% chg)

$-0.00 (-0.54%)
Prev Close
$0.28
Open
$0.28
Day's High
$0.28
Day's Low
$0.28
Volume
66,630
Avg. Vol
267,177
52-wk High
$1.63
52-wk Low
$0.24

Chart for

About

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more... (more)

Overall

Beta: -0.13
Market Cap(Mil.): $15.43
Shares Outstanding(Mil.): 55.29
Dividend: --
Yield (%): --

Financials

  TROV.OQ Industry Sector
P/E (TTM): -- 39.22 32.53
EPS (TTM): -0.53 -- --
ROI: -124.95 14.34 12.63
ROE: -256.75 17.22 14.50

BRIEF-Trovagene Completes First Dosing Cohort Of Patients In Phase 1B/2 Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF FIRST DOSING COHORT OF PATIENTS IN ONGOING PHASE 1B/2 TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

May 17 2018

BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class B Units Of Common Stock

* TROVAGENE INC FILES FOR OFFERING OF UP TO $15.0 MILLION OF CLASS A UNITS OF COMMON STOCK AND UP TO $15.0 MILLION OF CLASS B UNITS OF COMMON STOCK - SEC FILING Source text: [https://bit.ly/2rAnkbg] Further company coverage:

May 10 2018

BRIEF-Trovagene Reports Q1 Loss Per Share $0.09

* TROVAGENE ANNOUNCES FIRST QUARTER 2018 HIGHLIGHTS AND FINANCIAL RESULTS

May 08 2018

BRIEF-Trovagene Reports Q4 Loss Per Share $0.06

* TROVAGENE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

Feb 26 2018

BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

Feb 06 2018

BRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer

* TROVAGENE ANNOUNCES INITIATION OF UNITE PHASE 2 CLINICAL TRIAL OF PCM-075 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Source text for Eikon: Further company coverage:

Jan 24 2018

BRIEF-Trovagene Prices $4.5 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 15 MILLION SHARES OF ITS COMMON STOCK, COMMON WARRANTS TO PURCHASE UP TO 15 MILLION SHARES OF COMMON STOCK

Dec 15 2017

BRIEF-Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®

* TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Dec 14 2017

BRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium

* TROVAGENE PRESENTS DATA SHOWING SENSITIVITY OF TRIPLE NEGATIVE BREAST CANCER (TNBC) CELL LINES TO PCM-075 AND SYNERGY WITH ZYTIGA® AT SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) Source text for Eikon: Further company coverage:

Dec 07 2017

Earnings vs. Estimates